First Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach

Simple item page
dc.contributor.authorAmnuaywattakorn S.
dc.contributor.authorCharoenphun P.
dc.contributor.authorAtivitavas T.
dc.contributor.authorPasawang P.
dc.contributor.authorKhamwan K.
dc.contributor.authorThongpraparn T.
dc.contributor.authorKhiewvan B.
dc.contributor.authorRuangma P.
dc.contributor.authorChamroonrat W.
dc.contributor.authorChuamsaamarkkee K.
dc.contributor.correspondenceAmnuaywattakorn S.
dc.contributor.otherMahidol University
dc.date.accessioned2026-02-13T18:24:47Z
dc.date.available2026-02-13T18:24:47Z
dc.date.issued2026-02-01
dc.description.abstractProstate-specific membrane antigen (PSMA)-targeted radionuclide therapy has become an established treatment option for metastatic castration-resistant prostate cancer. Although lutetium-177 (<sup>177</sup>Lu) PSMA therapy has shown promising clinical benefits, terbium-161 (<sup>161</sup>Tb) PSMA is an emerging theranostic agent offering potential advantages due to its combination of beta and Auger electron emissions. This work presents the first documented case in Thailand and Southeast Asia of a patient treated at Ramathibodi Hospital with <sup>161</sup>Tb-PSMA following progression on <sup>177</sup>Lu-PSMA therapy. This report describes the clinical application of this novel radiopharmaceutical, the implementation of quantitative imaging protocols, single photon emission computed tomography/computed tomography calibration processes, and absorbed dose estimations from voxel-based dosimetry that contributed to individualised treatment planning.
dc.identifier.citationMolecular Imaging and Radionuclide Therapy Vol.35 No.1 (2026) , 78-83
dc.identifier.doi10.4274/mirt.galenos.2026.28863
dc.identifier.eissn21471959
dc.identifier.issn21461414
dc.identifier.scopus2-s2.0-105029260789
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/114996
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.titleFirst Southeast Asian Experience of Terbium-161 PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer (mCRPC): Quantitative Imaging and Dosimetric Approach
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105029260789&origin=inward
oaire.citation.endPage83
oaire.citation.issue1
oaire.citation.startPage78
oaire.citation.titleMolecular Imaging and Radionuclide Therapy
oaire.citation.volume35
oairecerif.author.affiliationFaculty of Medicine Ramathibodi Hospital, Mahidol University
oairecerif.author.affiliationFaculty of Medicine, Chulalongkorn University
oairecerif.author.affiliationFaculty of Medicine Siriraj Hospital, Mahidol University
oairecerif.author.affiliationBangkok Hospital Medical Center

Files

Collections

Scopus 2026